Bought
Maintained
Sold
Other funds holding PFE
VCM
VPM
Amundi's PFE Position: Q1 2026 in Review
Amundi reduced its Pfizer (PFE) stake by 13% in Q1 2026, selling an estimated $166M and leaving 40,825,470 shares worth $1.15B. The position accounts for 0.31% of the portfolio, ranked #59.
Amundi first reported a position in PFE in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.55B in Q4 2022. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Amundi held 40,825,470 shares of Pfizer worth $1.15B as of Q1 2026.
- Amundi sold 6,237,910 Pfizer shares in Q1 2026, an estimated $166M.
- Pfizer made up 0.31% of Amundi's portfolio in Q1 2026, its #59 holding.
- Amundi first reported a position in Pfizer in Q2 2021 and has held it in 20 quarters since.
- Amundi's Pfizer position peaked at $1.55B in Q4 2022.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.